Track Savara Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Savara Inc. SVRA · Stock Open Savara Inc. in new tab

4.64 USD
EPS
-0.58
P/B
9.68
ROE
-151.05
Beta
0.30
Target Price
11.06 USD
Loading chart...
Key Metrics
Earnings dateMarch 12, 2027
EPS-0.58
Book Value0.53
Price to Book9.68
Debt/Equity28.04
% Insiders2.552%
Estimates
Forward P/E-13.84
Forward EPS-0.37
Target Mean Price11.06

DCF valuation

Model fair value for Savara Inc. (SVRA)
Result
Sign in to run the valuation for SVRA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Strong buy · mean target 11.06 USD (low 9.00, high 16.00) · as of 10 Nov 2026
Low 9.00
Mean 11.06
High 16.00
Price 4.64
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Savara Inc. Logo Savara Inc. Analysis (SVRA)

United States Health Care Official Website Stock

Is Savara Inc. a good investment? Savara Inc. (SVRA) is currently trading at 4.64 USD. Market analysts have a consensus price target of 11.06 USD. This suggests a potential upside from current levels.

Earnings Schedule: Savara Inc. is expected to release its next earnings report on March 12, 2027. The market consensus estimate for Forward EPS is -0.37.

Investor FAQ

Does Savara Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Savara Inc.?

Savara Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 12, 2027. The company currently has a trailing EPS of -0.58.

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Exchange Ticker
MUN (Germany) YB4P.MU
STU (Germany) YB4P.SG
BER (Germany) YB4P.BE
FRA (Germany) YB4P.F
NMS (United States) SVRA
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
June 11, 2002 1:2
April 26, 2010 1:25
April 28, 2017 1:100
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion